Rincon lithium project: US$2.5bn cost, 60,000tpa capacity, DLE technology and 2028 production timeline
Read More Pharma Industry News Biohaven gets $400m near-term cash as SK Biopharmaceuticals takes opakalim rights SK Biopharmaceuticals will pay Biohaven $400 million in near-term cash and up to $395 million in additional milestones for global rights to opakalim and its Kv7 platform, while pivotal epilepsy data remain pending. bySrinathAugust 30, 2026